Search Results

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced the appointment of Vishwas Setia as Chief Financial Officer.

MapLight Therapeutics today announced initiation of a Phase 1 clinical trial evaluating ML-007/PAC, MapLight’s extended-release fixed-dose combination formulation of the novel, investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC).

MapLight Therapeutics today announced the closing of an oversubscribed $225 million Series C financing to continue the advancement of MapLight’s transformative treatments for neuropsychiatric and neurological conditions.

MapLight Therapeutics today announced completion of a Phase 1 clinical trial evaluating the bioavailability, safety, and tolerability of an extended release formulation of ML-007, a novel M1/M4 preferring muscarinic agonist, alone and when co-administered with a precision-matched muscarinic antagonist designed to offset peripheral effects.

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, announced the appointment of Tim Garnett, M.D. to its Board of Directors.

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, announced the appointment of Kris Hanson as the company’s General Counsel.

MapLight Therapeutics announced the appointment of Charmaine Lykins, MBA, as chief commercial officer, effective April 3,2023.

MapLight Therapeutics today announced completion of a second Phase 1 clinical trial evaluating ML-007, a novel M1/M4 muscarinic receptor agonist targeting brain circuits shown to be dysfunctional in neurodegenerative and neurocognitive disorders such as schizophrenia, Alzheimer’s disease psychosis, and dyskinesias.

MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4 muscarinic agonist that targets circuits thought to be disrupted in neurologic conditions such as schizophrenia and dyskinesia.

MapLight Therapeutics announced it has initiated a Phase 1 clinical trial evaluating ML-007, a novel therapeutic developed to target circuits understood to be dysfunctional in neurologic conditions such as schizophrenia and dyskinesias.